CoChat
Cited by 14

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Allosteric coupling asymmetry mediates paradoxical activation of BRAF by type II inhibitors

Rasmussen, Damien M, Semonis, Manny M, Greene, Joseph T, Muretta, Joseph M, Thompson, Andrew R, Toledo Ramos, Silvia, Thomas, David D, Pomerantz, William CK, Freedman, Tanya S, Levinson, Nicholas M · 2024 · eLife

Published version of a preprint

Abstract

The type II class of RAF inhibitors currently in clinical trials paradoxically activate BRAF at subsaturating concentrations. Activation is mediated by induction of BRAF dimers, but why activation rather than inhibition occurs remains unclear. Using biophysical methods tracking BRAF dimerization and conformation, we built an allosteric model of inhibitor-induced dimerization that resolves the allosteric contributions of inhibitor binding to the two active sites of the dimer, revealing key differences between type I and type II RAF inhibitors. For type II inhibitors the allosteric coupling between inhibitor binding and BRAF dimerization is distributed asymmetrically across the two dimer binding sites, with binding to the first site dominating the allostery. This asymmetry results in efficient and selective induction of dimers with one inhibited and one catalytically active subunit. Our allosteric models quantitatively account for paradoxical activation data measured for 11 RAF inhibitors. Unlike type II inhibitors, type I inhibitors lack allosteric asymmetry and do not activate BRAF homodimers. Finally, NMR data reveal that BRAF homodimers are dynamically asymmetric with only one of the subunits locked in the active αC-in state. This provides a structural mechanism for how binding of only a single αC-in inhibitor molecule can induce potent BRAF dimerization and activation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7554/elife.95481.2

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 51

  1. Brian, 2020, Immunopharmacology and quantitative analysis of tyrosine kinase signaling, Current Protocols in Immunology, 130, 10.1002/cpim.104 · DOI
  2. Brian, 2022, A dominant function of LynB kinase in preventing autoimmunity, Science Advances, 8, 10.1126/sciadv.abj5227 · DOI
  3. Brummer, 2020, RAF kinase dimerization: implications for drug discovery and clinical outcomes, Oncogene, 39, 4155, 10.1038/s41388-020-1263-y · DOI
  4. Chapman, 2011, Improved survival with vemurafenib in melanoma with BRAF V600E mutation, The New England Journal of Medicine, 364, 2507, 10.1056/NEJMoa1103782 · DOI · Paper page
  5. Cook, 2021, Inhibition of RAF dimers: it takes two to tango, Biochemical Society Transactions, 49, 237, 10.1042/BST20200485 · DOI
  6. Cotto-Rios, 2020, Inhibitors of BRAF dimers using an allosteric site, Nature Communications, 11, 10.1038/s41467-020-18123-2 · DOI
  7. Davies, 2002, Mutations of the BRAF gene in human cancer, Nature, 417, 949, 10.1038/nature00766 · DOI · Paper page
  8. Dummer, 2018, Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial, The Lancet. Oncology, 19, 603, 10.1016/S1470-2045(18)30142-6 · DOI · Paper page
  9. Ederer, 2007, Thermodynamically feasible kinetic models of reaction networks, Biophysical Journal, 92, 1846, 10.1529/biophysj.106.094094 · DOI
  10. Eisen, 2006, Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis, British Journal of Cancer, 95, 581, 10.1038/sj.bjc.6603291 · DOI · Paper page
  11. Hagelueken, 2012, MtsslWizard: in silico spin-labeling and generation of distance distributions in PyMOL, Applied Magnetic Resonance, 42, 377, 10.1007/s00723-012-0314-0 · DOI
  12. Haling, 2014, Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling, Cancer Cell, 26, 402, 10.1016/j.ccr.2014.07.007 · DOI · Paper page
  13. Hall-Jackson, 1999, Paradoxical activation of Raf by a novel Raf inhibitor, Chemistry & Biology, 6, 559, 10.1016/s1074-5521(99)80088-x · DOI · Paper page
  14. Hatzivassiliou, 2010, RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth, Nature, 464, 431, 10.1038/nature08833 · DOI · Paper page
  15. Hauschild, 2012, Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial, Lancet, 380, 358, 10.1016/S0140-6736(12)60868-X · DOI · Paper page
  16. Heidorn, 2010, Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF, Cell, 140, 209, 10.1016/j.cell.2009.12.040 · DOI · Paper page
  17. Hu, 2013, Allosteric activation of functionally asymmetric RAF kinase dimers, Cell, 154, 1036, 10.1016/j.cell.2013.07.046 · DOI · Paper page
  18. Jin, 2017, RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition, Nature Communications, 8, 10.1038/s41467-017-01274-0 · DOI
  19. Johnson, 2009, FitSpace explorer: an algorithm to evaluate multidimensional parameter space in fitting kinetic data, Analytical Biochemistry, 387, 30, 10.1016/j.ab.2008.12.025 · DOI · Paper page
  20. Joseph, 2010, The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner, PNAS, 107, 14903, 10.1073/pnas.1008990107 · DOI · Paper page
  21. Karoulia, 2016, An integrated model of RAF inhibitor action predicts inhibitor activity against oncogenic BRAF signaling, Cancer Cell, 30, 485, 10.1016/j.ccell.2016.06.024 · DOI · Paper page
  22. Kondo, 2019, Cryo-EM structure of a dimeric B-Raf:14-3-3 complex reveals asymmetry in the active sites of B-Raf kinases, Science, 366, 109, 10.1126/science.aay0543 · DOI · Paper page
  23. Lai, 2022, Classical RAS proteins are not essential for paradoxical ERK activation induced by RAF inhibitors, PNAS, 119, 10.1073/pnas.2113491119 · DOI
  24. Lavoie, 2013, Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization, Nature Chemical Biology, 9, 428, 10.1038/nchembio.1257 · DOI · Paper page
  25. Lavoie, 2015, Regulation of RAF protein kinases in ERK signalling, Nature Reviews. Molecular Cell Biology, 16, 281, 10.1038/nrm3979 · DOI · Paper page
  26. Lavoie, 2018, MEK drives BRAF activation through allosteric control of KSR proteins, Nature, 554, 549, 10.1038/nature25478 · DOI
  27. Liau, 2020, Dimerization induced by C-Terminal 14-3-3 binding is sufficient for BRAF kinase activation, Biochemistry, 59, 3982, 10.1021/acs.biochem.0c00517 · DOI
  28. Martinez Fiesco, 2022, Structural insights into the BRAF monomer-to-dimer transition mediated by RAS binding, Nature Communications, 13, 10.1038/s41467-022-28084-3 · DOI
  29. Nakamura, 2013, Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma, Cancer Research, 73, 7043, 10.1158/0008-5472.CAN-13-1825 · DOI
  30. Nazarian, 2010, Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation, Nature, 468, 973, 10.1038/nature09626 · DOI · Paper page
  31. Okaniwa, 2013, Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives, Journal of Medicinal Chemistry, 56, 6478, 10.1021/jm400778d · DOI
  32. Owsley, 2021, Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database, Experimental Biology and Medicine, 246, 31, 10.1177/1535370220959657 · DOI
  33. Park, 2019, Architecture of autoinhibited and active BRAF-MEK1-14-3-3 complexes, Nature, 575, 545, 10.1038/s41586-019-1660-y · DOI · Paper page
  34. Peng, 2015, Inhibition of RAF isoforms and active dimers by LY3009120 leads to anti-tumor activities in RAS or BRAF mutant cancers, Cancer Cell, 28, 384, 10.1016/j.ccell.2015.08.002 · DOI · Paper page
  35. Poulikakos, 2010, RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF, Nature, 464, 427, 10.1038/nature08902 · DOI · Paper page
  36. Proietti, 2020, Mechanisms of acquired BRAF inhibitor resistance in melanoma: a systematic review, Cancers, 12, 10.3390/cancers12102801 · DOI
  37. Rajakulendran, 2009, A dimerization-dependent mechanism drives RAF catalytic activation, Nature, 461, 542, 10.1038/nature08314 · DOI · Paper page
  38. Röring, 2012, Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling, The EMBO Journal, 31, 2629, 10.1038/emboj.2012.100 · DOI
  39. Rushworth, 2006, Regulation and role of Raf-1/B-Raf heterodimerization, Molecular and Cellular Biology, 26, 2262, 10.1128/MCB.26.6.2262-2272.2006 · DOI · Paper page
  40. Schaaf, 2017, Spectral unmixing plate reader: high-throughput, high-precision FRET assays in living cells, SLAS Discovery, 22, 250, 10.1177/1087057116679637 · DOI
  41. Su, 2012, RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors, The New England Journal of Medicine, 366, 207, 10.1056/NEJMoa1105358 · DOI · Paper page
  42. Sullivan, 2020, A phase i study of LY3009120, A Pan-RAF inhibitor, in patients with advanced or metastatic cancer, Molecular Cancer Therapeutics, 19, 460, 10.1158/1535-7163.MCT-19-0681 · DOI
  43. Thevakumaran, 2015, Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation, Nature Structural & Molecular Biology, 22, 37, 10.1038/nsmb.2924 · DOI · Paper page
  44. Thompson A. 2022. Venison. Software Heritage. swh:1:rev:652831dae45127fe2ff7cdf0188d9703d9e768f8. https://archive.softwareheritage.org/swh:1:dir:1d1c3270a76015e6f0a2b96ef99a7c134027e4e7;origin=https://github.com/thompsar/Venison;visit=swh:1:snp:71e7db0713a1908384d6d87dbe47c158ef2e85eb;anchor=swh:1:rev:652831dae45127fe2ff7cdf0188d9703d9e768f8.
  45. Tkacik, 2023, Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib, The Journal of Biological Chemistry, 299, 10.1016/j.jbc.2023.104634 · DOI
  46. Tsai, 2008, Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity, PNAS, 105, 3041, 10.1073/pnas.0711741105 · DOI · Paper page
  47. Wagle, 2011, Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling, Journal of Clinical Oncology, 29, 3085, 10.1200/JCO.2010.33.2312 · DOI · Paper page
  48. Wan, 2004, Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF, Cell, 116, 855, 10.1016/s0092-8674(04)00215-6 · DOI · Paper page
  49. Weber, 2001, Active ras induces heterodimerization of cRaf and BRaf, Cancer Research, 61, 3595
  50. Wellbrock, 2004, The RAF proteins take centre stage, Nature Reviews. Molecular Cell Biology, 5, 875, 10.1038/nrm1498 · DOI · Paper page
  51. Ye, 2017, Absorption, metabolism, and excretion of [14C]ponatinib after a single oral dose in humans, Cancer Chemotherapy and Pharmacology, 79, 507, 10.1007/s00280-017-3240-x · DOI

Cited by

Metadata

Authors
Rasmussen, D. M., Semonis, M. M., Greene, J. T., Muretta, J. M., Thompson, A. R., Toledo Ramos, S., Thomas, D. D., Pomerantz, W. C., Freedman, T. S., & Levinson, N. M.
Affiliations
  • Department of Pharmacology, University of Minnesota
  • Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota
  • Department of Chemistry, University of Minnesota
Venue
eLife
Published
2024-05-14
Volume
13
ISSN
2050-084X
Cited by
14
References
6
Language
en
Funders
  • National Cancer Institute (F31CA257218, R33CA246363)
  • National Institute of General Medical Sciences (T32GM132029, 5R35GM140837)
  • American Cancer Society – Kirby Foundation (PF-21-068-01-LIB)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR073966)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.